Loading [Contrib]/a11y/accessibility-menu.js
JHEOR
  • Menu
  • Articles
    • Author Correction
    • Autoimmune Diseases
    • Cardiovascular Conditions
    • Commentary
    • Dermatological Diseases
    • Endocrine Diseases
    • Gastrointestinal Conditions
    • General Indications
    • Hematology
    • Hereditary Genetic Disorders
    • Infectious Diseases
    • Methodology and Healthcare Policy
    • Nephrologic/Hepatologic Conditions
    • Neurological Diseases
    • Oncology
    • Ophthalmology
    • Other Conditions
    • Psychological Conditions
    • Respiratory Diseases
    • Trauma Induced Conditions
    • Urological/Gynecological Diseases
    • All
  • For Authors
  • Editorial Board
  • About
  • Issues
  • Blog
  • Journal Policies
  • For Reviewers
  • search

    Sorry, something went wrong. Please try your search again.
    ×

    • Articles
    • Blog posts

RSS Feed

Enter the URL below into your favorite RSS reader.

https://jheor.org/feed
×
Cardiovascular Conditions
Vol. 5, Issue 2, 2018 January 09, 2018 EDT

Using Real World Evidence to Describe Pulmonary Arterial Hypertension Treatment Patterns, Healthcare Resource Utilization, and Costs Associated with PDE-5 Inhibitor Monotherapy

George Ruiz , Jason Yeaw , Cassandra A. Lickert , Ajita P. De , Rolin L. Wade , Janis Pruett , William Drake ,
  • real world evidence
  • tadalafil
  • sildenafil
  • pulmonary arterial hypertension
  • healthcare utilization
ccby-4.0 • https://doi.org/10.36469/9812
JHEOR
1.
Ruiz G, Yeaw J, Lickert CA, et al. Using Real World Evidence to Describe Pulmonary Arterial Hypertension Treatment Patterns, Healthcare Resource Utilization, and Costs Associated with PDE-5 Inhibitor Monotherapy. JHEOR. 2018;5(2):206-219. doi:10.36469/9812
Save article as...▾
  • PDF
  • XML
  • Citation (BibTeX)
Powered by Scholastica, the modern academic journal management system